Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: A-001; A-002; LY-315920; LY-333013; S-3013; S-5920; Varespladib methyl

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly; Shionogi
  • Developer Anthera Pharmaceuticals; University Health Network
  • Class Acetic acids; Anti-inflammatories; Antirheumatics; Indoles; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lung injury

Highest Development Phases

  • Discontinued Acute coronary syndromes; Acute lung injury; Coronary artery disease; Multiple organ failure; Systemic inflammatory response syndrome

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 23 Mar 2012 Discontinued - Phase-III for Acute coronary syndromes in Australia (PO)
  • 23 Mar 2012 Discontinued - Phase-III for Acute coronary syndromes in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top